ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW 488,500
+16,500 (3.50%)
Oct 31, 2025, 3:30 PM KST
ALTEOGEN Revenue
ALTEOGEN had revenue of 18.64B KRW in the quarter ending June 30, 2025, with 52.39% growth. This brings the company's revenue in the last twelve months to 158.06B, up 74.10% year-over-year. In the year 2024, ALTEOGEN had annual revenue of 102.85B with 6.56% growth.
Revenue (ttm)
158.06B
Revenue Growth
+74.10%
P/S Ratio
159.71
Revenue / Employee
1.02B
Employees
155
Market Cap
25.24T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 102.85B | 6.33B | 6.56% |
| Dec 31, 2023 | 96.52B | 67.72B | 235.08% |
| Dec 31, 2022 | 28.81B | -9.94B | -25.65% |
| Dec 31, 2021 | 38.75B | -3.68B | -8.67% |
| Dec 31, 2020 | 42.43B | 13.20B | 45.15% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.03T |
| Celltrion | 3.75T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 620.28B |
| PharmaResearch | 449.81B |
| Sam Chun Dang Pharm. | 215.10B |
| LigaChem Biosciences | 148.28B |